(P<0.05).Conclusion:The FOLFIRINOX regimen is superior to the Gemcitabine and Capecitabine regimen in the treatment of stage Ⅳ pancreatic cancer,but the incidence of toxic side effects is relatively high,it is a better choice for general good condition patients with stage Ⅳ pancreatic cancer.%...
the high incidence of toxic side effects and the same problem of drug resistance make this regimen notoriously limited in clinical treatments. Especially, in contrast to the numerous studies on the mechanism of gemcitabine resistance
22 Considering the true 12-month PFS proportion under novel treatment regimen to be 0.66, 46 patients were necessary to achieve 81% power to conclude the 12-month PFS rate is indeed greater than 0.5 (rate under the null hypothesis) assuming a 1-sided alternative and α level of .10. More...
Cholangiocarcinoma (CCA) is a rare biliary tract cancer with a low five-year survival rate and high recurrence rate after surgical resection. Currently treatment approaches include systemic chemotherapeutics such as FOLFIRINOX, a chemotherapy regimen is
However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase Ⅲ trial showing an improved outcome over gemcitabine, the ...
However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase 鈪 trial showing an improved outcome over gemcitabine, the ...
These innovative drug-loaded nanoparticles achieved higher antitumor efficacy and showed minimal side effects compared with the FOLFIRINOX regimen alone. Our study suggested that the multiple layer-by-layer hybrid nanoparticles have great potential for improving the chemotherapeutic efficacy for the patients ...
The regimen is well tolerated without febrile neutropenia with prophylactic pegteograstim. Further analysis of efficacy will be presented.Clinical trial information: NCT04611724.Jae-Lyun LeeAsan Medical Center, University of Ulsan College of Medicine, Seoul, South KoreaInkeun Park...
The FOLFIRINOX (a combination of 5-fluorouracil, irinotecan, and oxaliplatin) chemotherapy regimen is a validated first-line treatment option. We investigated the impact of sarcopenia on overall survival (OS) and progression-free survival (PFS) in patients with metastatic pancreatic carcinoma. Clinical...